Glutaminase Inhibition Represents Novel Treatment Strategy in NFE2L2- and KEAP1-Mutated NSCLC
July 30th 2022Jonathan Wesley Riess, MD, MS, discusses a phase 1 trial examining the combination of sapanisertib and telaglenastat, and explains why glutaminase inhibition is being investigated as a novel way to treat select patients with non–small cell lung cancer.
EGFR TKI–Based Combos Could Lead to More Tailored First-Line Treatment Options in EGFR-Mutated NSCLC
July 29th 2022Leveraging EGFR TKIs as a backbone for combination therapies will be pivotal for expanding treatment options and delivering more personalized therapies in the first-line setting for patients with non–small cell lung cancer harboring EGFR mutations.
Novel Biomarker Testing Could Enhance Immunotherapy Treatment Decisions in NSCLC
July 29th 2022PD-L1 and tumor mutational burden are established biomarkers for leveraging immunotherapy in non–small cell lung cancer; however, their use may not be appropriate in determining treatment decisions for all patients.
HER2-Mutated NSCLC Treatment Evolves From Mainstay TKIs to Novel ADCs and Beyond
July 29th 2022Antibody-drug conjugates have demonstrated substantial activity in patients with HER2-mutated non–small cell lung cancer, with fam-trastuzumab deruxtecan-nxki showcasing the strongest response rate and progression-free survival benefit to date.
Value of Biomarkers for Immunotherapy in Advanced NSCLC Continue to Evolve
July 28th 2022Traditional predictive biomarkers for the efficacy of peri-operative immunotherapy for patients with advanced non–small cell lung cancer, such as PD-L1 expression, still hold value but newer biomarker candidates such as minimal residual disease are starting to make an impact.
KRAS Inhibitors Reach New Milestones in NSCLC
July 31st 2021Significant advances have been made regarding the development of KRAS G12C inhibitors in non–small cell lung cancer in recent years, explained Karen L. Reckamp, MD, who added that research regarding predictive co-mutations, acquired resistance, and combination strategies is expected to propel the utility of these agents even further.